The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles
Reuters: China’s economy cools sharply in April as lockdowns bite
April industrial output -2.9% y/y vs f’cast +0.4% April retail sales -11.1% y/y vs f’cast -6.1% Nationwide jobless rate highest since Feb 2020 Jan-April fixed asset investment +6.8% y/y, vs f’cast +7.0% Read Here
Reuters: Furor erupts in Italy over euro zone bailout fund reform
Proposals to reform the euro zone’s bailout fund are creating a political storm in Italy, where parties and institutions are battling over whether Rome should try to block the reform at the EU level. Read […]
The Irish Times: Ireland and Spain seek ‘urgent review’ of Israel trade over EU deal’s human rights obligations
February 14, 2024
Mathew D. Rose
Economics, EU politics, EU-Institutions, Finance, National Politics, Racism
0
Varadkar and Spanish PM Sanchez ask for ‘appropriate measures’ to be taken if conditions of agreement have been broken Read HERE
Be the first to comment